These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 25122428)

  • 21. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade.
    Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R
    Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations.
    Krencz I; Sztankovics D; Danko T; Sebestyen A; Khoor A
    Cancer Metastasis Rev; 2021 Dec; 40(4):1141-1157. PubMed ID: 34958428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
    Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
    Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
    Stjernström A; Karlsson C; Fernandez OJ; Söderkvist P; Karlsson MG; Thunell LK
    Cancer Med; 2014 Apr; 3(2):337-48. PubMed ID: 24500884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.
    Sozopoulos E; Litsiou H; Voutsinas G; Mitsiades N; Anagnostakis N; Tseva T; Patsouris E; Tseleni-Balafouta S
    Endocr Pathol; 2010 Jun; 21(2):90-100. PubMed ID: 20186503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.
    Zhou Z; Zhu L; Niu X; Shen S; Zhao Y; Zhang J; Ye J; Han-Zhang H; Liu J; Liu C; Lu S
    Thorac Cancer; 2019 Apr; 10(4):839-847. PubMed ID: 30793508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.
    Heavey S; O'Byrne KJ; Gately K
    Cancer Treat Rev; 2014 Apr; 40(3):445-56. PubMed ID: 24055012
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Amato O; Buisseret L; Gebhart G; Plouznikoff N; Larsimont D; Awada A; Piccart M; Aftimos P
    Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 36863843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
    Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
    Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
    Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
    Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.
    Scrima M; De Marco C; Fabiani F; Franco R; Pirozzi G; Rocco G; Ravo M; Weisz A; Zoppoli P; Ceccarelli M; Botti G; Malanga D; Viglietto G
    PLoS One; 2012; 7(2):e30427. PubMed ID: 22363436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.
    Hou MM; Liu X; Wheler J; Naing A; Hong D; Coleman RL; Tsimberidou A; Janku F; Zinner R; Lu K; Kurzrock R; Fu S
    Oncotarget; 2014 Nov; 5(22):11168-79. PubMed ID: 25426553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
    Wojtalla A; Fischer B; Kotelevets N; Mauri FA; Sobek J; Rehrauer H; Wotzkow C; Tschan MP; Seckl MJ; Zangemeister-Wittke U; Arcaro A
    Clin Cancer Res; 2013 Jan; 19(1):96-105. PubMed ID: 23172887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of PI3K-Akt/mTOR/AMPK signaling pathway genetic mutation with efficacy and prognosis in nasopharyngeal carcinoma.
    Chen Y; He Q; Ma H; Zhang L; Liu F; Han Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):165-173. PubMed ID: 35545406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
    Ng CKY; Piscuoglio S; Geyer FC; Burke KA; Pareja F; Eberle CA; Lim RS; Natrajan R; Riaz N; Mariani O; Norton L; Vincent-Salomon A; Wen YH; Weigelt B; Reis-Filho JS
    Clin Cancer Res; 2017 Jul; 23(14):3859-3870. PubMed ID: 28153863
    [No Abstract]   [Full Text] [Related]  

  • 36. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
    Marquard FE; Jücker M
    Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.
    Park S; Shim JH; Lee B; Cho I; Park WY; Kim Y; Lee SH; Choi Y; Han J; Ahn JS; Ahn MJ; Park K; Sun JM
    Lung Cancer; 2019 Aug; 134():7-15. PubMed ID: 31319998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
    APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care.
    Pirozzi F; Berkseth M; Shear R; Gonzalez L; Timms AE; Sulc J; Pao E; Oyama N; Forzano F; Conti V; Guerrini R; Doherty ES; Saitta SC; Lockwood CM; Pritchard CC; Dobyns WB; Novotny E; Wright JNN; Saneto RP; Friedman S; Hauptman J; Ojemann J; Kapur RP; Mirzaa GM
    Brain; 2022 Apr; 145(3):925-938. PubMed ID: 35355055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
    Ogino A; Choi J; Lin M; Wilkens MK; Calles A; Xu M; Adeni AE; Chambers ES; Capelletti M; Butaney M; Gray NS; Gokhale PC; Palakurthi S; Kirschmeier P; Oxnard GR; Sholl LM; Jänne PA
    Mol Oncol; 2021 Jan; 15(1):27-42. PubMed ID: 32191822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.